William H. Carson, M.D


William H. Carson, M.D. has served as the Chairman of the Board of Otsuka Pharmaceutical Development & Commercialization, Inc. since January 2020. From 2010 to 2019, Dr. Carson served as president and CEO of Otsuka Pharmaceutical Development & Commercialization, Inc. Under his leadership, Dr. Carson brought several products to market, including the first digital medicine approved by the FDA, Abilify Mycite® (aripiprazole tablets with sensor).

Dr. Carson is a board member of Excision Biotherapeutics, Saama Technologies and Internet2, and an advisor to Artis Ventures, a venture capital firm that focuses on health and technology innovations. He previously served on the board of Prevail Therapeutics which was acquired by Eli Lilly. Dr. Carson is also chairman of the Sozosei Foundation, the philanthropic arm of Otsuka America Pharmaceutical, Inc., and Board Chair Emeritus of the Sphinx Organization, which is dedicated to diversity in the arts. He holds a Bachelor of Arts in History and Science from Harvard College and completed his medical degree from Case Western Reserve University School of Medicine, followed by his residency in psychiatry at Tufts / New England Medical Center. He was on faculty at the Medical University of South Carolina in the Department of Psychiatry and Behavioral Sciences from 1988 to 1998 before joining the pharmaceutical industry in 1998 in the Pharmaceutical Research Institute at Bristol-Myers Squibb. He then joined Otsuka in 2002.